Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

MoonLake Immunotherapeutics (MLTX) Equity Ratio (2020 - 2026)

MoonLake Immunotherapeutics' Equity Ratio history spans 7 years, with the latest figure at 0.63 for Q1 2026.

  • Quarterly Equity Ratio fell 21.38% to 0.63 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.63 through Mar 2026, down 21.38% year-over-year, with the annual reading at 0.72 for FY2025, 23.27% down from the prior year.
  • Equity Ratio came in at 0.63 for Q1 2026, down from 0.72 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.99 in Q2 2023 to a low of 0.11 in Q1 2022.
  • The 5-year median for Equity Ratio is 0.93 (2022), against an average of 0.82.
  • The largest YoY upside for Equity Ratio was 13390.28% in 2022 against a maximum downside of 5092.45% in 2022.
  • MoonLake Immunotherapeutics' Equity Ratio stood at 0.89 in 2022, then rose by 8.98% to 0.98 in 2023, then decreased by 4.13% to 0.93 in 2024, then decreased by 23.27% to 0.72 in 2025, then fell by 11.56% to 0.63 in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Equity Ratio are 0.63 (Q1 2026), 0.72 (Q4 2025), and 0.7 (Q3 2025).